OncoMatch/Clinical Trials/NCT06136364
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Is NCT06136364 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAR-T for t-lymphoblastic lymphoma.
Treatment: CAR-T — To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 overexpression (CD7+ by flow cytometry or IHC)
The tumor cells detected by bone marrow flow cytometry were CD7+ and/or extramedullary lesions were diagnosed as CD7+ by pathological immunohistochemistry at the time of enrollment and screening
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard induction chemotherapy
patients who have received at least two courses standard induction regimen and failed to achieve a complete response or complete remission was not achieved after first-line or above salvage treatment
Cannot have received: CAR-T cell therapy
Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening
Lab requirements
Blood counts
HGB at least 70g/L, PLT 50x10^9/L, can be transfused
Kidney function
Creatinine <1.5×ULN or creatinine clearance rate(Cockroft-Gault)>50ml/min
Liver function
Total bilirubin <3×ULN; ALT/AST<3×ULN
Cardiac function
Oxygen saturation under air ≥ 92%; LVEF≥50%
Oxygen saturation under air ≥ 92%; LVEF≥50%; Total bilirubin <3×ULN; ALT/AST<3×ULN; Creatinine <1.5×ULN or creatinine clearance rate(Cockroft-Gault)>50ml/min; HGB at least 70g/L,PLT 50x109/L, can be transfused
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify